Highlights

  • US benchmark indices retreated from record levels despite selective sector gains.
  • BioMarin and Ionis shares recorded day gains, outperforming the NASDAQ-100 Index.
  • Trading volumes showed mixed participation compared with historical averages.

US equity markets pulled back on Wednesday as early-year momentum moderated across several segments. The S&P 500 declined 0.34% to close at 6,920.93, while the Dow Jones Industrial Average fell 466 points, or 0.94%, to 48,996.08. Both indices had touched fresh all-time highs earlier in the session before reversing course. In contrast, the Nasdaq Composite edged higher, gaining 0.16% to finish at 23,584.27, supported by selective advances in technology and healthcare names.

BioMarin Pharmaceutical (NASDAQ:BMRN) Gains 2%

BioMarin Pharmaceutical Inc. shares rose USD 1.38, or 2.3%, to close at USD 61.45. The stock’s performance exceeded that of the NASDAQ-100 Index, which advanced 0.2% on the day, resulting in a relative gain of approximately 2.1%.

Trading activity totaled 1.34 million shares, representing about 0.6 times the stock’s average daily volume of 2.18 million shares. The company’s market capitalisation stood at around USD 12 billion at the close. BioMarin operates within the medical and biomedical sector, where it is ranked mid-range by market capitalisation among peers. The stock traded within its established 52-week range of USD 50.76 to USD 73.51.

Ionis Pharmaceuticals (NASDAQ:IONS) Extends Momentum

Ionis Pharmaceuticals Inc. also posted gains, with its shares rising USD 2.19, or 2.7%, to close at USD 83.68. Relative to the NASDAQ-100 Index, the stock recorded a 2.5% outperformance on the day.

The stock remained above its 200-day moving average price of USD 50.89 for a second consecutive session, with the price-to-moving-average ratio rising to 1.64. Intraday volatility reached 4.5%, exceeding its average daily volatility of 3.8%. Ionis traded between a high of USD 86.15 and a low of USD 82.40 during the session.

Total trading volume reached 2.39 million shares, or about 1.2 times its average daily volume, with traded value of approximately USD 200.2 million. Over the past year, Ionis shares have shown substantial price appreciation, reflecting a marked change from levels seen in early 2025.